Insulin pharmacokinetics

Insulin Therapy

Volumn , Issue , 2002, Pages 73-86

  Wittlin, Steven D ^a   Woehrle, Hans J ^a   Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4143132875     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am 26: 575-598, 1997.
2. Davidson JK, Anderson JHJ Jr, Chance RE. Insulin therapy. In: Davidson JK, ed. Clinical Diabetes Mellitus: A Problem-Oriented Approach. 3rd ed. New York: Thieme, pp 329-403, 2000.
3. Bliss M. The Discovery of Insulin. Toronto: McClelland and Stewart, 1982.
4. Best CH. The first clinical use of insulin. Diabetes 5: 65-67, 1956.
5. Deckert T. Intermediate-acting insulin preparations: NPH and lente. Diabetes Care 3: 623-626, 1980.
6. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6: 374-377, 1983.
7. Heinemann L, Richter B. Clinical pharmacology of human insulin. Diabetes Care 16(suppl 1): 90-100, 1993.
8. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 4: 366-376, 1981.
9. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49: 2142-2148, 2000.
10. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 5: 77-91, 1982.
11. Barnett AH, Owens DR. Insulin analogues. Lancet 349: 47-51, 1997.
12. Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med 337: 176-183, 1997.
13. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42: 1151-1167, 1999.
14. Bolli GB, Owens DR. Insulin glargine. Lancet 356: 443-445, 2000.
15. Setter SM, Corbett CF, Campbell RK, White JR. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 34: 1423-1431, 2000.
16. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13: 923-954, 1990.
17. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]- human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43: 396-402, 1994.
18. Ter Braak EW, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JH, Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 19: 1437-1440, 1996.
19. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R. Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46: 265-270, 1997.
20. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 157: 1249-1255, 1997.
21. Heller SR, Amiel SA, Mansell P. U.K. Lispro Study Group. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care 22: 1607-1611, 1999.
22. Gale EA. The UK Trial Group. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type I diabetes on intensified insulin therapy. Diabet Med 17: 209-214, 2000.
23. Brunelle BL, Llewelyn J, Anderson JH Jr, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type I diabetes. Diabetes Care 21: 1726-1731, 1998.
24. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45: 1750-1754, 1996.
25. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. German Humalog-CSII Study Group. Use of insulin lispro in continuous subcutaneous insulin treatment: results of a multicenter trial. Diabetes Care 22: 784-788, 1999.
26. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Taiber JP. The Study Group for the Development of Pump Therapy in Diabetes. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type I diabetic patients on intensified treatment: a randomized study. Diabetes Care 23: 1232-1235, 2000.
27. Rassam AG, Zeise TM, Burge MR, Schade DS. Optimal administration of lispro insulin in hyperglycemic type I diabetes. Diabetes Care 22: 133-136, 1999.
28. Simpson KL, Spencer CM. Insulin aspart. Drugs 57(5): 759-765, 1999.
29. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999-1005, 2000.
30. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 10: 535-539, 1993.
31. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 22: 1501-1506, 1999.
32. Hedmann CA, Lindstorm T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type I diabetes. Diabetic Care 24: 1120-1121, 2001.
33. Home PD, Lindholm A, Hylleberg B, Round P. UK Insulin Aspart Study Group. Improved glycemic control with insulin aspart: a multicenter randomized doubleblind crossover trial in type I diabetic patients. Diabetes Care 21: 1904-1909, 1998.
34. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fastacting insulin analog, as the mealtime insulin in the management of patient with type I diabetes. Diabetes Care 23: 583-588, 2000.
35. Bode BW, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 24: 69-72, 2001.
36. Hallas-Moller K, Petersen K, Schlichtkrull J. Crystalline and amorphous insulinzinc compounds with prolonged action. Science 116: 394-398, 1952.
37. Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Mem Hosp 1: 60-73, 1946.
38. Hagedorn HC. Modification of insulin. Phys Bull 12: 26-33, 1947.
39. Scott DA, Fisher AL. Studies on insulin with protamine. J Pharmacol Exp Ther 58: 78-92, 1936.
40. Heine RJ, Bilo HJ, Fonk T, van der Veen EA, van der Meer J. Absorption kinetics and action profiles of mixtures of short and intermediate-acting insulins. Diabetologia 27: 558-562, 1984.
41. Tunbridge F, Newens A, Home P, Davis S, Murphy M, Burrin JM, Alberti KG, Jensen I. A comparison of human ultralente- and lente-based twice-daily injection regimens. Diabet Med 6: 496-501, 1989.
42. Raskin P, Klaff L, Bergenstal R, Halle J, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetic Care 23: 1666-1671, 2000.
43. Ratner R, Hirsh I, Neifing J, Garg S, Mecca T, Wilson C. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23: 639-643, 2000.
44. Rosenstock J, Park G, Zimmerman J. U.S. Insulin Glargine (HOE 901) Type I Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 23: 1137-1142, 2000.
45. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23: 1130-1136, 2000.
46. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24: 631-636, 2001.
47. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Timeaction profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 23: 644-649, 2000.
48. Hermansen K, Madsbad S, Perrild H, Kristeusen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care 24: 296-301, 2001.